The review begins where the technology itself began: in prokaryotes. CRISPR-Cas systems evolved as adaptive immune defenses in bacteria and archaea, storing fragments of viral DNA in genomic memory banks and using them to recognize and destroy invading genetic material. When researchers realized that this bacterial immune machinery could be reprogrammed with a single guide RNA to target nearly any sequence of interest, the implications were enormous. Early CRISPR-Cas9 experiments demonstrated remarkable efficiency and ease of use compared with earlier genome-editing platforms such as zinc-finger nucleases and transcription activator-like effector nucleases, which required laborious protein engineering for each new target.

Yet the honeymoon was short-lived. As clinical ambitions grew, so did concern over off-target effects, the unwanted edits that occur when the Cas9 nuclease acts at sites that only partially match the guide RNA. Variable editing outcomes, unpredictable insertions and deletions at the target site, and the risk of large genomic rearrangements all limited the technology’s broader application to human therapy. The review emphasizes that these technical shortcomings, alongside delivery inefficiencies that make it difficult to get editing machinery into the right cells in the right tissues, remain among the field’s most persistent challenges even as the toolkit has grown far more sophisticated.

The evolution from scissors to editors is best embodied by the rise of base editing and prime editing. Rather than relying on double-strand breaks and the cell’s error-prone repair pathways, these newer approaches chemically convert individual DNA letters or write short new sequences with minimal collateral damage. The review highlights work demonstrating that prime editing can correct oncogenic KRAS variants without the constraints imposed by traditional CRISPR-Cas9 workflows, and that CRISPR-based strategies have achieved efficient correction of both KRAS and TP53 mutations, two of the most frequently mutated genes in human cancer. Such results illustrate the conceptual shift: the goal is no longer simply to disrupt a gene but to rewrite it precisely, restoring normal function rather than merely silencing a faulty instruction.

Cancer therapy has emerged as one of the most active arenas for these refined tools. The review surveys how CRISPR-Cas9 library screening has accelerated anti-cancer drug discovery by systematically identifying genes that tumors depend on, and how ex vivo editing of immune cells is reshaping immunotherapy. Chimeric antigen receptor T cells engineered with CRISPR have shown that targeting the CAR construct to a defined genomic locus, such as the TRAC locus, can enhance tumor rejection compared with randomly integrated vectors. Editing of natural killer cells and T cells from human donors is being pursued for cancer immunotherapy, and strategies to improve CAR-T cell persistence through CRISPR-mediated knockout of exhaustion-related pathways are advancing through preclinical and clinical pipelines.

Beyond cancer, the review catalogs applications across viral disease, autoimmune conditions and inherited disorders. CRISPR-based approaches are being developed to engineer resistance to viruses, with HIV-1/AIDS therapy representing a prominent example in which editing aims to remove or disable viral genomes integrated into host DNA. Diagnostic platforms derived from CRISPR nucleases, including SHERLOCK and DETECTR, exploit the sequence-specific recognition of Cas enzymes to detect viral nucleic acids with high sensitivity, offering rapid tools for emerging infectious diseases. In autoimmune disease research, genome editing is being used to dissect and potentially correct the immune dysregulation that underlies conditions such as lupus and rheumatoid arthritis, pointing toward a future in which the immune system itself can be retuned at the genetic level.

None of these therapeutic visions can be realized without solving the delivery problem, and the review devotes substantial attention to the technologies that ferry editing machinery into cells. Viral vectors, particularly adeno-associated virus and lentiviral vectors, offer efficient gene transfer but raise questions about payload capacity, insertional risks and immune responses. Non-viral alternatives include physical methods such as electroporation and microinjection, lipid nanoparticles and solid lipid nanoparticles, cell-penetrating peptides, DNA nanocarriers and extracellular vesicles. Nanotechnology-based delivery of CRISPR components for cancer treatment is a particularly active frontier, with gold nanoparticles and other platforms being evaluated for biocompatibility and cytotoxicity under evolving regulatory frameworks. The choice of delivery vehicle, the review makes clear, often determines whether an elegant editing strategy can ever reach the clinic.

Even when editing succeeds, the human body may object. Immunogenicity of the bacterial Cas9 protein is a recognized concern, since many people carry pre-existing antibodies and T cells reactive to common Cas variants from environmental exposure to the microbes that harbor them. The review also confronts the ethical dimensions that shadow every advance in the field. The prospect of human germline and heritable genome editing has prompted a global policy debate about where the lines should be drawn, and ethicists have argued that the moral considerations raised by such a powerful tool demand attention to accessibility, consent and the long-term consequences of permanent genomic change. Who will be able to afford these therapies, and how societies will govern their use, remain unresolved questions that the technical community cannot answer alone.

What emerges from the review is a portrait of a technology on a clear trajectory. Engineered Cas variants, such as PAM-flexible chimeric Cas9 proteins that relax the sequence constraints on where editing can occur, are expanding the addressable space of the genome. High-fidelity nucleases reduce off-target activity, base and prime editors increase the precision of the intended change, and improved delivery systems broaden the range of treatable tissues. Together these refinements position CRISPR as an increasingly precise platform for both fundamental research and therapeutic use, supporting targeted therapies for genetic disorders in ways that the original scissor paradigm could never achieve. The authors, based at the University of Science and Culture and the Royan Institute in Tehran, frame this progression not as a completed project but as an ongoing evolution toward greater specificity, safety and predictability.

The clinical momentum is already visible. Approved CRISPR-based therapies for hemoglobin disorders have demonstrated that genome editing can deliver durable benefit in patients, and dozens of trials are testing edited cell therapies, in vivo editing and CRISPR-enabled diagnostics across a widening spectrum of disease. The remaining obstacles, off-target editing, delivery inefficiency, immune reactions and equitable access, are formidable but no longer conceptual; they are engineering and policy problems with active research programs attached to each. As Rahbari, Lohrasbi and Amiri-Yekta conclude, the story of therapeutic genome editing is one of steady refinement, in which the crude power of the original molecular scissors is being progressively replaced by the controlled, predictable hand of a true genome editor. The precision revolution they describe is redefining what medicine can attempt at the level of DNA itself, and the pace of that redefinition shows no sign of slowing.

Subject of Research: The evolution of CRISPR-based genome editing from early nuclease cutting tools toward precise therapeutic platforms for genetic disease

Article Title: From scissors to editors: how the evolution of precision is redefining therapeutic genome editing

Article References: Rahbari, M., Lohrasbi, R., & Amiri-Yekta, A. (2026). From scissors to editors: how the evolution of precision is redefining therapeutic genome editing. Molecular Genetics and Genomics, 301(1), Article 193. https://doi.org/10.1007/s00438-026-02467-3

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02467-3

Keywords: CRISPR-Cas9, genome editing, gene therapy, base editing, prime editing, off-target effects, cancer immunotherapy, CAR-T cells, viral vectors, nanoparticle delivery, precision medicine, genetic disorders

Cas9 enzymes, central to the CRISPR genome editing revolution, function as molecular scissors that can be guided to specific loci on the DNA to introduce targeted modifications. The most commonly deployed Cas9 protein, derived from Streptococcus pyogenes (SpCas9), has transformed molecular biology but is not without its limitations. SpCas9 is relatively large and sometimes challenging to deliver efficiently into cells, especially for therapeutic purposes where delivery vectors like adeno-associated viruses have strict size constraints. Furthermore, off-target effects and epigenetic manipulation limitations have spurred ongoing quests for more efficient, precise, and smaller Cas variants. This new research breathes new life into these inquiries by resurrecting an ancestral Cas9 enzyme that is notably miniature yet catalytically robust.

The concept of "resurrection" here refers to the computational reconstruction and laboratory synthesis of an evolutionary ancestor that likely existed millions of years ago. Using phylogenetic inference and ancestral sequence reconstruction methods, Butterfield and Gersbach identified a common ancestor within the Cas9 family that exhibits distinct structural features enabling a more compact form factor. This ancestral enzyme, while smaller, maintains the essential domains responsible for DNA binding and cleavage, circumventing compromises usually encountered in engineered Cas variants where size reduction can come at the cost of activity or specificity.

Extensive biochemical characterization revealed that this resurrected miniature Cas9 maintains robust nuclease activity, effectively introducing double-stranded breaks at targeted genomic loci with high fidelity. Moreover, its compactness facilitates more efficient packaging into viral vectors commonly employed in gene therapy, including the favored adeno-associated virus (AAV). The smaller size also broadens delivery options, enhancing prospects for in vivo editing strategies in tissue types previously difficult to target due to size limitations.

One of the most exciting facets of this resurrected Cas9 ancestor is its expanded utility in epigenome editing. Unlike traditional editing that merely cuts DNA, epigenome editing aims to modify DNA-associated proteins and chemistry to regulate gene expression without altering the underlying sequence. By fusing the miniature Cas9 to epigenetic effector domains, the researchers demonstrated targeted modulation of chromatin states, activating or repressing genes with remarkable spatial and temporal precision. This ability paves the way for potentially reversible and tunable therapies for diseases rooted in aberrant gene regulation, including cancers, neurological disorders, and developmental abnormalities.

Additionally, the ancestral enzyme showcased reduced immunogenicity in preliminary assays, an attribute critical for clinical applications. Modern Cas9 proteins sometimes elicit immune responses due to their bacterial origin, which can limit efficacy and safety in patients. Evolutionarily distant ancestors may present novel epitopes less likely to be recognized by the human immune system, thereby enhancing the safety profile of gene therapies employing these tools.

Structurally, high-resolution crystallography provided insights into the unique folding and active site morphology of the resurrected Cas9. Despite its small size, the enzyme preserves the quintessential bilobed architecture, integrating Recognition (REC) and Nuclease (NUC) lobes, essential for target DNA engagement and cleavage activity. Intriguingly, certain domain arrangements differ markedly from modern Cas9s, suggesting evolutionary optimizations that balance compactness with catalytic efficiency, which bioengineers could exploit in further tailoring endonucleases for specific applications.

The team also performed comprehensive genome-wide off-target analyses using state-of-the-art unbiased detection methods. Results indicated that this miniature Cas9 exhibits heightened specificity, with significantly fewer off-target cleavages compared to SpCas9 and other engineered variants. Such precision is paramount for clinical translation because unintended DNA alterations can have oncogenic or otherwise deleterious consequences. The structural determinants underpinning this specificity remain a topic for future investigation, but the initial data are promising for safer gene editing.

Beyond human therapeutics, the resurrected enzyme holds transformative potential in agricultural biotechnology. Its compactness and efficiency allow for more straightforward delivery to plant cells, where genome modifications can enhance crop resilience, productivity, and nutritional value. Furthermore, epigenetic editing capabilities might enable transient modifications that do not involve DNA sequence changes, facilitating regulatory approval and public acceptance in genetically engineered organisms.

An intriguing aspect explored by the authors involves the co-evolution of CRISPR-Cas systems and their microbial hosts. By comparing this ancestral Cas9 to homologs from extant bacteria, the research sheds light on how evolutionary pressures sculpted enzyme properties such as size, specificity, and activity to counter phage attacks effectively. This evolutionary context not only informs basic microbiology but also inspires novel engineering strategies, effectively harnessing natural diversity to overcome current technical bottlenecks.

The ability to resurrect and functionally characterize ancient biomolecules exemplifies the fusion of computational biology, synthetic biology, and structural biochemistry. It is an emblematic advance showcasing the power of interdisciplinary approaches in expanding the molecular toolbox available for precision medicine. By bridging millions of years of evolutionary history, the team has provided a new starting point for innovation beyond incremental modifications of existing proteins.

Looking forward, the researchers envisage multiple avenues to further refine and deploy their resurrected Cas9 ancestor. These include adapting the enzyme for base editing and prime editing platforms, which allow single-nucleotide changes without DNA breaks, and expanding epigenomic engineering to incorporate diverse effector domains for tailored gene expression programs. Scaling up delivery methods and refining specificity in complex in vivo systems remain high priorities as the technology edges closer to human trials.

The implications of this research resonate well beyond the laboratory. As the scientific community pushes toward realizing the promise of gene therapies for previously intractable conditions, tools that improve delivery, reduce off-target effects, and expand functional versatility become crucial. This resurrected miniature Cas9 could be the foundation of next-generation biomedical interventions, fueling treatments for genetic diseases, cancer, and beyond.

In the broader frame of genome engineering, this work exemplifies a paradigm shift from merely optimizing contemporary proteins to uncovering latent evolutionary solutions encoded in ancestral sequences. By tapping into nature’s deep molecular heritage, researchers can circumvent contemporary protein design limitations, uncover new functions, and revolutionize the scope and precision of genomic and epigenomic manipulation technologies.

In conclusion, Butterfield and Gersbach’s resurrection of a miniature Cas9 ancestor not only redefines possibilities in genome and epigenome editing but also sets a precedent for future endeavors seeking to harness evolution as a toolkit for molecular engineering. This elegant synthesis of ancient sequences and cutting-edge technology illuminates a promising path toward more efficient, safer, and versatile genome editing platforms that could transform medicine, agriculture, and fundamental biology in the coming decades.

Subject of Research: Resurrected miniature Cas9 enzyme for enhanced genome and epigenome editing.

Article Title: Resurrecting a miniature Cas9 ancestor for genome and epigenome editing.

Article References:
Butterfield, G.L., Gersbach, C.A. Resurrecting a miniature Cas9 ancestor for genome and epigenome editing. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02707-8

Image Credits: AI Generated